A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AbbVie
- 21 Mar 2018 Planned End Date changed from 1 Nov 2020 to 16 Jul 2020.
- 21 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2017 Planned End Date changed from 22 Dec 2020 to 1 Nov 2020.